TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$397.4m

TScan Therapeutics Future Growth

Future criteria checks 2/6

TScan Therapeutics's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 24.5% per year. EPS is expected to grow by 5.5% per annum. Return on equity is forecast to be -123.9% in 3 years.

Key information

-4.1%

Earnings growth rate

5.5%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate24.5%
Future return on equity-123.9%
Analyst coverage

Low

Last updated11 Mar 2024

Recent future growth updates

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Recent updates

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Mar 23
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Feb 17
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Earnings and Revenue Growth Forecasts

NasdaqGM:TCRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202613-128-101N/A3
12/31/202516-119-108N/A4
12/31/202418-103-96N/A4
12/31/202321-89-65-61N/A
9/30/202317-88-58-54N/A
6/30/202316-82-82-79N/A
3/31/202317-73-74-70N/A
12/31/202214-66-71-67N/A
9/30/202213-62-70-65N/A
6/30/202212-61-67-62N/A
3/31/202211-57-66-59N/A
12/31/202110-49-59-49N/A
9/30/20218-42-51-42N/A
6/30/20216-34-43-34N/A
3/31/20213-29-14-8N/A
12/31/20201-26-7-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TCRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TCRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TCRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TCRX's revenue (24.5% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: TCRX's revenue (24.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TCRX is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.